$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

$pbyi Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000143774924014395 Filed on May 02, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$47.08M	$43.77M
YoY Change	-13.72%	-17.07%
Cost Of Revenue	$10.66M	$10.73M
YoY Change	-10.11%	-18.84%
Gross Profit	$36.43M	$33.04M
YoY Change	-14.72%	-16.48%
Gross Profit Margin	77.36%	75.49%
Selling, General & Admin	$24.97M	$21.75M
YoY Change	2.08%	-3.27%
% of Gross Profit	68.56%	65.83%
Research & Development	$13.63M	$13.59M
YoY Change	2.06%	6.93%
% of Gross Profit	37.42%	41.13%
Depreciation & Amortization	$100.0K	$100.0K
YoY Change	0.0%	0.0%
% of Gross Profit	0.27%	0.3%
Operating Expenses	$38.60M	$35.34M
YoY Change	2.08%	0.41%
Operating Profit	-$2.179M	-$2.299M
YoY Change	-144.54%	-152.67%
Interest Expense	-$2.128M	$3.359M
YoY Change	-164.0%	1.42%
% of Operating Profit
Other Income/Expense, Net	-$1.972M	-$2.296M
YoY Change	-23.54%	-18.49%
Pretax Income	-$4.151M	-$4.595M
YoY Change	-279.46%	-396.83%
Income Tax	$378.0K	$220.0K
% Of Pretax Income
Net Earnings	-$4.529M	-$4.815M
YoY Change	-313.03%	-443.68%
Net Earnings / Revenue	-9.62%	-11.0%
Basic Earnings Per Share	-$0.09	-$0.10
Diluted Earnings Per Share	-$0.09	-$0.10
COMMON SHARES
Basic Shares Outstanding	48.24M	48.21M
Diluted Shares Outstanding	48.29M	48.19M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$96.83M	$107.2M
YoY Change	30.08%	50.47%
Cash & Equivalents	$67.15M	$76.75M
Short-Term Investments	$29.68M	$30.41M
Other Short-Term Assets	$241.0K	$255.0K
YoY Change	-57.94%	-43.21%
Inventory	$9.049M	$7.100M
Prepaid Expenses	$3.493M	$3.924M
Receivables	$28.11M	$24.58M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$137.7M	$143.0M
YoY Change	16.17%	27.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$680.0K	$757.0K
YoY Change	-30.4%	-25.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.370M	$4.907M
YoY Change	-17.72%	5.3%
Total Long-Term Assets	$67.28M	$71.12M
YoY Change	-17.89%	-15.83%
TOTAL ASSETS
Total Short-Term Assets	$137.7M	$143.0M
Total Long-Term Assets	$67.28M	$71.12M
Total Assets	$205.0M	$214.1M
YoY Change	2.25%	9.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.50M	$8.964M
YoY Change	73.19%	4.37%
Accrued Expenses	$39.01M	$37.72M
YoY Change	9.89%	10.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$45.33M	$45.33M
YoY Change	300.01%
Total Short-Term Liabilities	$104.3M	$98.19M
YoY Change	73.0%	103.77%
LONG-TERM LIABILITIES
Long-Term Debt	$43.74M	$54.69M
YoY Change	-50.09%	-44.55%
Other Long-Term Liabilities	$121.0K	$10.29M
YoY Change	-99.45%	-56.42%
Total Long-Term Liabilities	$43.86M	$54.69M
YoY Change	-49.95%	-44.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$104.3M	$98.19M
Total Long-Term Liabilities	$43.86M	$54.69M
Total Liabilities	$156.5M	$163.2M
YoY Change	-8.0%	-4.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.355B	-$1.350B
YoY Change	-0.64%	-1.13%
Common Stock	$1.403B	$1.401B
YoY Change	0.68%	0.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.51M	$50.98M
YoY Change
Total Liabilities & Shareholders Equity	$205.0M	$214.1M
YoY Change	2.25%	9.12%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$4.529M	-$4.815M
YoY Change	-313.03%	-443.68%
Depreciation, Depletion And Amortization	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Cash From Operating Activities	$1.027M	$11.20M
YoY Change	-68.84%	330.77%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$0.00
YoY Change	-70.59%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$723.0K	-$19.08M
YoY Change	-115.67%	285.45%
Cash From Investing Activities	$703.0K	-$19.08M
YoY Change	-115.01%	9.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-11.33M	$0.00
YoY Change
NET CHANGE
Cash From Operating Activities	1.027M	$11.20M
Cash From Investing Activities	703.0K	-$19.08M
Cash From Financing Activities	-11.33M	$0.00
Net Change In Cash	-9.602M	-$7.834M
YoY Change	592.29%	-47.09%
FREE CASH FLOW
Cash From Operating Activities	$1.027M	$11.20M
Capital Expenditures	$20.00K	$0.00
Free Cash Flow	$1.007M	$11.20M
YoY Change	-68.8%	-213.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	990000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	881000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48214663
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48214663
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47646787
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47646787
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	2100000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	9700000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	9700000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9700000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	9700000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2024Q1	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	2000000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Trd Arr Ind Name TrdArrIndName	Allison Dorval
CY2024Q1	ecd	Trd Arr Ind Title TrdArrIndTitle	Board Member
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2024Q1	ecd	Trd Arr Adoption Date TrdArrAdoptionDate	March 6, 2024
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Trd Arr Expiration Date TrdArrExpirationDate	June 30, 2024
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-35703
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0683487
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	10880 Wilshire Boulevard, Suite 2150
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
CY2024Q1	dei	City Area Code CityAreaCode	424
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	248-6500
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	PBYI
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48238850
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76751000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84585000	usd
CY2024Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	30412000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	11354000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24584000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	47837000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	7100000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7080000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3924000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4417000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	255000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	912000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	143026000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	156185000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7023000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7792000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	757000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	855000	usd
CY2024Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	58436000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	60871000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2091000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2091000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2816000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2734000	usd
CY2024Q1	us-gaap	Assets Assets	214149000	usd
CY2023Q4	us-gaap	Assets Assets	230528000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8964000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6889000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37716000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52721000	usd
CY2024Q1	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	1205000	usd
CY2023Q4	pbyi	Post Marketing Commitment Liability Current PostMarketingCommitmentLiabilityCurrent	975000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4977000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4800000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	45329000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	33997000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	98191000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	99382000	usd
CY2024Q1	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	121000	usd
CY2023Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	121000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5738000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7034000	usd
CY2024Q1	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	4426000	usd
CY2023Q4	pbyi	Postmarketing Commitment Liability Noncurrent PostmarketingCommitmentLiabilityNoncurrent	4890000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	54691000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	65659000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	163167000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	177086000	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1400982000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1398605000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1349979000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1345164000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	50982000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	53442000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	214149000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	230528000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	43766000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	52775000	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10728000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13218000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21750000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22486000	usd
CY2024Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	13587000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12706000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	46065000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	48410000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2299000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4365000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	972000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	537000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3359000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3312000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	91000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2296000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2817000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4595000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1548000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	220000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	147000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4815000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1401000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.1
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.1
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48189256
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46636083
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48189256
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47157904
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4815000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1401000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-22000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4837000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1401000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	53442000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2377000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-22000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4815000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	50982000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	21608000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2838000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1401000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	25847000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4815000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1401000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2897000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2878000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2377000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2838000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	110000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-23143000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9186000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	20000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-635000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-411000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-870000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-657000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1980000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2075000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2149000	usd
CY2024Q1	pbyi	Increase Decrease In Operating Lease Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet	350000	usd
CY2023Q1	pbyi	Increase Decrease In Operating Lease Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet	250000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-15005000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-18811000	usd
CY2024Q1	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-234000	usd
CY2023Q1	pbyi	Increase Decrease In Postmarketing Commitment Liability IncreaseDecreaseInPostmarketingCommitmentLiability	-233000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11246000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2643000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	24974000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	4950000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	5894000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	-0	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12500000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-19080000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17450000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7834000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14807000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	86676000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	78792000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	78842000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	63985000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	2907000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2907000	usd
CY2024Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	122000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48189256
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	142000	usd
CY2024Q1	pbyi	Number Of Subsidiaries NumberOfSubsidiaries	1	pure
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4800000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11200000	usd
CY2024Q1	pbyi	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	107200000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Use of Estimates: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) in the United States, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;"> </p>
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7939340000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7262499000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4815000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	1401000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46636083
CY2024Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	521821
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48189256
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47157904
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.1
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.1
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2024Q1	pbyi	Sublease Agreement Potential Milestone Payments SubleaseAgreementPotentialMilestonePayments	579800000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	2100000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	79819000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	26000	usd
CY2024Q1	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	79793000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	48916000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	usd
CY2023Q4	pbyi	Cash Cash Equivalents And Shortterm Investments Fair Value CashCashEquivalentsAndShorttermInvestmentsFairValue	48912000	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Concentration of Risk: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured <span style="background-color:#ffffff;">limits at </span><em style="font: inherit;"> March 31, 2024</em><span style="background-color:#ffffff;"> were approximately </span>$78.1<span style="background-color:#ffffff;"> million. The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. While the drug candidates were being developed by Pfizer, both the drug substance and drug product are manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX and intends to use <em style="font: inherit;">third</em> party contractors to manufacture, supply, store and distribute drug supplies for its clinical trials of alisertib. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2024Q1	pbyi	Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits	78100000	usd
CY2024Q1	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	6000	usd
CY2023Q4	pbyi	Prepaid Cro Services Current PrepaidCROServicesCurrent	6000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4499000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5693000	usd
CY2024Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2113000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	820000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	488000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	567000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	7100000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	7080000	usd
CY2024Q1	pbyi	Average Incremental Borrowing Rate AverageIncrementalBorrowingRate	0.109	pure
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	7300000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	9700000	usd
CY2024Q1	pbyi	Finitelived Intangible Asset Expected Amortization Year Six FinitelivedIntangibleAssetExpectedAmortizationYearSix	2400000	usd
CY2024Q1	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	20136000	usd
CY2023Q4	pbyi	Trade Accounts Receivable Net Excluding License Revenue Receivable TradeAccountsReceivableNetExcludingLicenseRevenueReceivable	27669000	usd
CY2024Q1	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	5438000	usd
CY2023Q4	pbyi	Royalty Revenue Receivable RoyaltyRevenueReceivable	21049000	usd
CY2024Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	25574000	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	48718000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	990000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	881000	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	24584000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	47837000	usd
CY2024Q1	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	523000	usd
CY2023Q4	pbyi	Prepaid Other Clinical Development Current PrepaidOtherClinicalDevelopmentCurrent	534000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1023000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1403000	usd
CY2024Q1	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	482000	usd
CY2023Q4	pbyi	Prepaid Professional Fess Current PrepaidProfessionalFessCurrent	1081000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1890000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1393000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3924000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4417000	usd
CY2024Q1	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	32000	usd
CY2023Q4	pbyi	Prepaid Cro Services Noncurrent PrepaidCROServicesNoncurrent	0	usd
CY2024Q1	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	210000	usd
CY2023Q4	pbyi	Prepaid Other Clinical Development Expense Noncurrent PrepaidOtherClinicalDevelopmentExpenseNoncurrent	210000	usd
CY2024Q1	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2574000	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2524000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2816000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2734000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	6740000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	7151000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1578000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109	pure
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	4386000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5983000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1508000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11877000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1162000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	10715000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	762000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1044000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	266000	usd
CY2024Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2072000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8535000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8535000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7778000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7680000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	757000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	855000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2024Q1	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	102500000	usd
CY2023Q4	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	102500000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	44064000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	41629000	usd
CY2024Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	58436000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	60871000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P6Y
CY2024Q1	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	7794000	usd
CY2023Q4	pbyi	Accrued Legal Verdict Expense Current AccruedLegalVerdictExpenseCurrent	7706000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7450000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	16496000	usd
CY2024Q1	pbyi	Accrued Development Costs AccruedDevelopmentCosts	1110000	usd
CY2023Q4	pbyi	Accrued Development Costs AccruedDevelopmentCosts	940000	usd
CY2024Q1	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	8631000	usd
CY2023Q4	pbyi	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	9388000	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1803000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5900000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4480000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4379000	usd
CY2024Q1	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	2104000	usd
CY2023Q4	pbyi	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	1044000	usd
CY2024Q1	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	525000	usd
CY2023Q4	pbyi	Accrued Professional Fees Liability Current AccruedProfessionalFeesLiabilityCurrent	245000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2615000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1589000	usd
CY2024Q1	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	585000	usd
CY2023Q4	pbyi	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	4521000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	619000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	513000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37716000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52721000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	121000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	121000	usd
CY2024Q1	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	121000	usd
CY2023Q4	pbyi	Accrued Liabilities Noncurrent AccruedLiabilitiesNoncurrent	121000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	37837000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	52842000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	102000000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1980000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	45329000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	54691000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	33997000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	45329000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	22674000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	102000000	usd
CY2024Q1	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	3430000	usd
CY2023Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	3066000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1980000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2344000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2011Q4	pbyi	Ordinary Shares Ownership Percentage OrdinarySharesOwnershipPercentage	0.20	pure
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2377000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2838000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.57
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.17
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	706980
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.46
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	441430
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.57
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	352146
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	3.71
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	796264
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	3.97
CY2024Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000	usd
CY2014Q3	pbyi	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	187500000	usd
CY2020Q2	pbyi	Percentage Of Unpaid Portion Of Milestone Payments Interest Rate PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate	0.0625	pure
CY2021Q3	pbyi	Milestone Payment MilestonePayment	1800000	usd
CY2024Q1	ecd	Trd Arr Securities Agg Avail Amt TrdArrSecuritiesAggAvailAmt	11000

Files In Submission

Name	View Source	Status
0001437749-24-014395-index-headers.html	Edgar Link	pending
0001437749-24-014395-index.html	Edgar Link	pending
0001437749-24-014395.txt	Edgar Link	pending
0001437749-24-014395-xbrl.zip	Edgar Link	pending
ex_647802.htm	Edgar Link	pending
ex_647803.htm	Edgar Link	pending
ex_647804.htm	Edgar Link	pending
ex_647805.htm	Edgar Link	pending
ex_661883.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbyi-20240331.xsd	Edgar Link	pending
pbyi20240331_10q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pbyi-20240331_cal.xml	Edgar Link	unprocessable
pbyi-20240331_def.xml	Edgar Link	unprocessable
pbyi-20240331_lab.xml	Edgar Link	unprocessable
pbyi-20240331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pbyi20240331_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2024 Q2 Form 10-Q Financial Statement

#000143774924014395 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI PUMA BIOTECHNOLOGY, INC. Stock $pbyi

2024 Q2 Form 10-Q Financial Statement

#000143774924014395 Filed on May 02, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBYI
PUMA BIOTECHNOLOGY, INC. Stock $pbyi